Trineumin
Phase 2Small molecule
Trineumin is one of 4 small molecule programs targeting Neurofibromatosis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in Neurofibromatosis
#DrugCompanyPhaseTrials
1Rapamune
PPrism Pharmaceuticals
Approved
Koselugo
AstraZenecaPhase 2
Gomekli
SSpringWorks Therapeutics, Inc.
Phase 2
Trineumin
PPRG Science & Technology Co., Ltd.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Trineumin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details